CTOs on the Move

NeoPharm

www.neopharm.com

 
NeoPharm, Inc. is a Waukegan, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.neopharm.com
  • 1850 S Lakeside Dr
    Waukegan, IL USA 60085
  • Phone: 847.887.0800

Executives

Name Title Contact Details

Similar Companies

ReproSource

ReproSource is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EdiGENE

EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.

Encodia

Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.

Thrive Earlier Detection

A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.

Phio Pharmaceuticals

Developing the next generation of immuno-oncology therapeutics